Response to interferon-alpha 2a in patients with e antigen-negative chronic hepatitis B

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis B is a significant global health concern.
• Interferon therapy is a treatment option for chronic hepatitis B.
• Hepatitis B e antigen (HBeAg) status and precore mutations can influence treatment response.

Purpose of the Study:

• To evaluate the efficacy of recombinant interferon-alpha 2a in chronic hepatitis B patients.
• To compare treatment outcomes based on HBeAg status.
• To investigate the role of precore mutations in interferon response.

Main Methods:

• Sixty-eight chronic hepatitis B patients received recombinant interferon-alpha 2a.
• HBeAg status and serum transaminase levels were monitored.
• Hepatitis B virus DNA clearance was assessed.
• Precore region mutations (G1896 vs. A1896) were analyzed using restriction fragment length polymorphism.

Main Results:

• HBeAg-negative patients showed higher rates of serum transaminase normalization and viral DNA clearance compared to HBeAg-positive patients.
• Patients with the precore A1896 mutation (stop codon) demonstrated a more favorable response to interferon.
• Lower pretreatment viral markers and rapid decrease post-interferon were observed in HBeAg-negative patients with the A1896 mutation.

Conclusions:

• HBeAg-negative chronic hepatitis B patients may benefit more from interferon therapy.
• The precore stop codon 28 mutant (A1896) appears sensitive to interferon treatment.
• Further research into genotype-specific responses to interferon is warranted.